within Pharmacolibrary.Drugs.ATC.N;

model N04BA03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.0005666666666666667,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0145,
    Tlag           = 900,            
    Vdp             = 0.034,
    k12             = 69,
    k21             = 69
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N04BA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>A combination therapy for Parkinson's disease consisting of levodopa, a dopamine precursor, administered with a dopa decarboxylase inhibitor (such as carbidopa or benserazide) to prevent peripheral conversion of levodopa to dopamine, and a catechol-O-methyltransferase (COMT) inhibitor (such as entacapone or tolcapone) to further prolong levodopa's plasma half-life. This combination is widely used and approved for managing motor symptoms in Parkinson's disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for adult patients with Parkinson's disease, co-administered orally as levodopa/carbidopa/entacapone fixed-dose formulation.</p><h4>References</h4><ol><li><p>Tambasco, N, et al., &amp; Calabresi, P (2018). Levodopa in Parkinson&#x27;s Disease: Current Status and Future Developments. <i>Current neuropharmacology</i> 16(8) 1239–1252. DOI:<a href=\"https://doi.org/10.2174/1570159X15666170510143821\">10.2174/1570159X15666170510143821</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28494719/\">https://pubmed.ncbi.nlm.nih.gov/28494719</a></p></li><li><p>Nutt, JG (2000). Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. <i>Neurology</i> 55(11 Suppl 4) S33–S41. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11147508/\">https://pubmed.ncbi.nlm.nih.gov/11147508</a></p></li><li><p>Tuunainen, J, et al., &amp; Yliperttula, M (2023). Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects. <i>European journal of drug metabolism and pharmacokinetics</i> 48(1) 23–34. DOI:<a href=\"https://doi.org/10.1007/s13318-022-00800-w\">10.1007/s13318-022-00800-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36309950/\">https://pubmed.ncbi.nlm.nih.gov/36309950</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N04BA03;
